A phase 2 trial to assess the efficacy and safety of ALD-403 when administered subcutaneously to patients with frequent episodic migraine
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2015
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Alder Biopharmaceuticals
- 13 Oct 2015 According to Alder BioPharmaceuticals media release, company is planning to initiate this trial in 2016.
- 13 Oct 2015 Planned initiation date changed from 1 Jan 2015 to 1 Jan 2016, as per Alder Biopharmaceuticals media release.
- 07 May 2015 According to Alder BioPharmaceuticals media release, top-line data is anticipated in the second half of 2016.